These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25546799)

  • 1. Subcutaneous immunoglobulin loading regimens for previously untreated patients with primary antibody deficiency.
    Rojavin M; Sidhu J; Pfister M; Hubsch A
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):146-8. PubMed ID: 25546799
    [No Abstract]   [Full Text] [Related]  

  • 2. Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.
    von Gunten S
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):151-2. PubMed ID: 25546801
    [No Abstract]   [Full Text] [Related]  

  • 3. Europe immunoglobulin map.
    Šedivá A; Chapel H; Gardulf A;
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):141-3. PubMed ID: 25546797
    [No Abstract]   [Full Text] [Related]  

  • 4. 7th International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):162. PubMed ID: 25546805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG replacement therapy, no size fits all.
    Bonilla FA
    Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunoglobulin replacement therapy in antibody deficiency syndromes: are we really doing enough?
    Baumann U; Miescher S; Vonarburg C
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):83-5. PubMed ID: 25546772
    [No Abstract]   [Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7th International Immunoglobulin Conference: Immunoglobulin in clinical practice.
    Shapiro RS; Borte M
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):86. PubMed ID: 25546773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible Hypogammaglobulinemia in 2 Pediatric Patients With Primary Immunodeficiency.
    Pasic S
    J Investig Allergol Clin Immunol; 2017; 27(5):320-321. PubMed ID: 29057740
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antibodies: biology and clinical use].
    De Martino M; Rossi ME; Vierucci A
    Ann Sclavo Collana Monogr; 1984; 1(1):1-305. PubMed ID: 6546001
    [No Abstract]   [Full Text] [Related]  

  • 11. Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.
    Melamed I; Testori A; Spirer Z
    Int Rev Immunol; 2012 Dec; 31(6):451-61. PubMed ID: 23215767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose and outcomes in primary immunodeficiency disorders.
    Bonagura VR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):7-9. PubMed ID: 25546743
    [No Abstract]   [Full Text] [Related]  

  • 13. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent Skin Pouches Following Subcutaneous Immunoglobulin Infusions in a Girl with Immunodeficiency, Bullous Skin Lesions and Melanosis Oculi.
    Krüger R; Feiterna-Sperling C; Blume-Peytavi U; Lala B; von Bernuth H; Wahn V
    J Clin Immunol; 2017 Aug; 37(6):505-507. PubMed ID: 28624913
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of intravenous and subcutaneous human immunoglobulins].
    Ramus B; Benbrahim O; Chérin P
    Soins; 2019 Mar; 64(833):13-18. PubMed ID: 30879622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Another subcutaneous immune globulin (Cuvitru) for primary immunodeficiency.
    Med Lett Drugs Ther; 2017 May; 59(1521):e88-e89. PubMed ID: 28520701
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies.
    Seppänen M
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):10-3. PubMed ID: 25546744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.